Ascendis Pharma A/S annual operating margin
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Ascendis Pharma A/S's operating margin was −18.92% for fiscal 2025.
View full Ascendis Pharma A/S company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −18.92% | +57.74 pp |
| 2024 | 2024-12-31 | −76.66% | +94.14 pp |
| 2023 | 2023-12-31 | −170.79% | +927.06 pp |
| 2022 | 2022-12-31 | −1,097.85% | +4710.74 pp |
| 2021 | 2021-12-31 | −5,808.59% | −1053.52 pp |
| 2020 | 2020-12-31 | −4,755.07% | −3059.97 pp |
| 2019 | 2019-12-31 | −1,695.10% | −232.50 pp |
| 2018 | 2018-12-31 | −1,462.59% | +5827.67 pp |
| 2017 | 2017-12-31 | −7,290.26% | −5707.11 pp |
| 2016 | 2016-12-31 | −1,583.15% | −1067.94 pp |
| 2015 | 2015-12-31 | −515.21% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | 4.00% | +3.78 pp |
| Q3 2025 | 2025-09-30 | 5.15% | +172.43 pp |
| Q2 2025 | 2025-06-30 | −33.50% | +336.68 pp |
| Q1 2025 | 2025-03-31 | −103.23% | −51.98 pp |
| Q4 2024 | 2024-12-31 | 0.22% | +26.81 pp |
| Q3 2024 | 2024-09-30 | −167.28% | +112.54 pp |
| Q2 2024 | 2024-06-30 | −370.18% | −73.01 pp |
| Q1 2024 | 2024-03-31 | −51.25% | +376.52 pp |
| Q4 2023 | 2023-12-31 | −26.59% | +617.14 pp |
| Q3 2023 | 2023-09-30 | −279.82% | +665.28 pp |
| Q2 2023 | 2023-06-30 | −297.17% | +2006.29 pp |
| Q1 2023 | 2023-03-31 | −427.77% | +1447.28 pp |
| Q4 2022 | 2022-12-31 | −643.72% | +1655.26 pp |
| Q3 2022 | 2022-09-30 | −945.09% | +7763.98 pp |
| Q2 2022 | 2022-06-30 | −2,303.46% | +9206.23 pp |
| Q1 2022 | 2022-03-31 | −1,875.06% | +14834.06 pp |
| Q4 2021 | 2021-12-31 | −2,298.98% | +15578.22 pp |
| Q3 2021 | 2021-09-30 | −8,709.07% | −5849.99 pp |
| Q2 2021 | 2021-06-30 | −11,509.69% | −5733.43 pp |
| Q1 2021 | 2021-03-31 | −16,709.12% | −13419.00 pp |
| Q4 2020 | 2020-12-31 | −17,877.20% | −15290.52 pp |
| Q3 2020 | 2020-09-30 | −2,859.09% | −450.93 pp |
| Q2 2020 | 2020-06-30 | −5,776.25% | −4170.06 pp |
| Q1 2020 | 2020-03-31 | −3,290.11% | −2250.57 pp |
| Q4 2019 | 2019-12-31 | −2,586.68% | −2245.71 pp |
| Q3 2019 | 2019-09-30 | −2,408.16% | +189026.84 pp |
| Q2 2019 | 2019-06-30 | −1,606.20% | +250854.91 pp |
| Q1 2019 | 2019-03-31 | −1,039.55% | +124581.88 pp |
| Q4 2018 | 2018-12-31 | −340.97% | +11030.46 pp |
| Q3 2018 | 2018-09-30 | −191,435.00% | −184183.16 pp |
| Q2 2018 | 2018-06-30 | −252,461.11% | −246905.48 pp |
| Q1 2018 | 2018-03-31 | −125,621.43% | −119287.83 pp |
| Q4 2017 | 2017-12-31 | −11,371.43% | — |
| Q3 2017 | 2017-09-30 | −7,251.84% | — |
| Q2 2017 | 2017-06-30 | −5,555.63% | — |
| Q1 2017 | 2017-03-31 | −6,333.60% | — |
Over the last five reported fiscal years, Ascendis Pharma A/S's operating margin increased from −4,755.07% to −18.92%, a change of +4736.15 percentage points. The latest reported quarter, Q4 2025, shows 4.00%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Ascendis Pharma A/S filings at SEC.gov ↗